ProPhase Net Debt from 2010 to 2026
| PRPH Stock | USD 0.16 0.01 5.88% |
Net Debt | First Reported 1996-12-31 | Previous Quarter 7.7 M | Current Value 7.3 M | Quarterly Volatility 11.2 M |
Check ProPhase Labs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProPhase Labs' main balance sheet or income statement drivers, such as Interest Expense of 4 M, Selling General Administrative of 32.4 M or Total Revenue of 7.4 M, as well as many indicators such as Price To Sales Ratio of 2.33, Dividend Yield of 0.13 or PTB Ratio of 2.15. ProPhase financial statements analysis is a perfect complement when working with ProPhase Labs Valuation or Volatility modules.
ProPhase | Net Debt | Build AI portfolio with ProPhase Stock |
The Net Debt trend for ProPhase Labs offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether ProPhase Labs is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest ProPhase Labs' Net Debt Growth Pattern
Below is the plot of the Net Debt of ProPhase Labs over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. ProPhase Labs' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProPhase Labs' overall financial position and show how it may be relating to other accounts over time.
| Net Debt | 10 Years Trend |
|
Net Debt |
| Timeline |
ProPhase Net Debt Regression Statistics
| Arithmetic Mean | 5,528,674 | |
| Geometric Mean | 2,813,909 | |
| Coefficient Of Variation | 206.47 | |
| Mean Deviation | 9,182,520 | |
| Median | (272,000) | |
| Standard Deviation | 11,415,104 | |
| Sample Variance | 130.3T | |
| Range | 34.4M | |
| R-Value | 0.80 | |
| Mean Square Error | 49.2T | |
| R-Squared | 0.65 | |
| Significance | 0.0001 | |
| Slope | 1,817,349 | |
| Total Sum of Squares | 2084.9T |
ProPhase Net Debt History
Other Fundumenentals of ProPhase Labs
ProPhase Labs Net Debt component correlations
Click cells to compare fundamentals
About ProPhase Labs Financial Statements
Investors use fundamental indicators, such as ProPhase Labs' Net Debt, to determine how well the company is positioned to perform in the future. Although ProPhase Labs' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Net Debt | 27.5 M | 28.9 M | |
| Net Debt To EBITDA | (0.67) | (0.70) |
Currently Active Assets on Macroaxis
When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:Check out the analysis of ProPhase Labs Correlation against competitors. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is there potential for Pharmaceuticals market expansion? Will ProPhase introduce new products? Factors like these will boost the valuation of ProPhase Labs. Anticipated expansion of ProPhase directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (19.80) | Revenue Per Share | Quarterly Revenue Growth (0.38) | Return On Assets |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between ProPhase Labs' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ProPhase Labs should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, ProPhase Labs' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.